BioNTech SE Q2 FY26 earnings call BNTX

BioNTech announced the appointment of Guido Oelkers as its next Chief Executive Officer, effective February 1, 2027, at the latest. This transition reflects the company's natural evolution from a pioneering research organization to a global biopharmaceutical company with multiple commercial products. The Supervisory Board selected Mr. Oelkers for his proven strategic leadership, ability to scale a global biopharmaceutical business, and strong track record in innovation-driven organizations, aiming to position BioNTech for its next phase of growth and multiproduct development by 2030.

The company is accelerating late-stage development of its oncology assets, shifting to a tumor-centric clinical development approach focusing on cancers with high unmet medical need. This strategy leverages a diversified toolkit of modalities, including next-generation immunomodulators, ADCs, and mRNA cancer immunotherapies. BioNTech aims to advance multiple assets into late-stage development, with a growing share of its multiproduct portfolio now in pivotal trials, and is generating novel-novel combination data to inform future registrational trials.

Encouraging global Phase II data for pumitamig (PD-L1 and VEGFA bispecific immunomodulator) in first-line non-small cell lung cancer (NSCLC) were presented at ASCO, showing robust clinical activity across PD-L1 expression levels, particularly in PD-L1 low disease. The data demonstrated meaningful consistency between results generated in China and globally across three key tumor types (SCLC, NSCLC, TNBC), increasing confidence in pumitamig's global potential. Four registrational programs for pumitamig in lung cancer are currently underway.

Updated data from the nonpivotal Stage 1 of PRESERVE-003, a global Phase III trial for gotistobart (selective Treg depleting antibody targeting CTLA-4) in metastatic squamous NSCLC, showed durable disease control with a 12-month PFS rate of 25% versus 0% for docetaxel. Gotistobart reduced the risk of death by 54% compared to docetaxel, with 63% of patients alive at 12 months versus 30% in the docetaxel arm. These data reinforce its potential as a chemo-free treatment option, with the pivotal Stage 2 interim analysis expected towards year-end.

The first patient was dosed in a Phase III clinical trial for Elfetabart Drozuntecan (Elfe-D), a B7-H3 targeted ADC, evaluating it against docetaxel in metastatic castration-resistant prostate cancer (mCRPC). This represents the first Phase III indication for Elfe-D, targeting a patient population with substantial unmet need and strong B7-H3 expression. The growing clinical evidence demonstrates antitumor activity across multiple indications with a favorable safety profile, and combination studies with pumitamig are ongoing.

BioNTech reported Q2 FY26 revenues of EUR 106 million, down from EUR 261 million in the prior year, mainly due to lower COVID-19 vaccine demand. Full-year 2026 revenue guidance was revised down to EUR 1.6 billion - EUR 1.9 billion, and adjusted R&D expenses were revised to EUR 2 billion - EUR 2.3 billion, reflecting pipeline prioritization. Despite these changes, the company maintains a strong financial position with EUR 16.6 billion in cash and investments, supporting R&D, external opportunities, and a EUR 1 billion share repurchase program, of which EUR 162 million has been executed.